ADCT: ADC Therapeutics S.A. P/S Multiple

Brandmark of ADC Pharma (ADCT)

The prospects for ADC Therapeutics (ADCT) depend on the approval of new drugs and the efficacy of its targeted technologies. The price-to-sales ratio demonstrates the resilience of the quotes, with the indicator settling at 2.00. Financial stability is based on unique methods of delivering toxins into cells and the active expansion of sales to combat pressure from major players in the hematology sector.

ADCT (ADC Therapeutics SA) P/S Multiple history from 07/04/2022 to 11/14/2026

ADC Therapeutics Corp (ADCT) - metric breakdowns and financial figures

- stock price and consensus target price:
Share Price adctherapeutics.com|ADCT - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization ADC Therapeutics Corp|ADCT - Enterprise Value
- balance sheet equity data:
Equity per Share ADC Therapeutics|ADCT - Book Capitalization|Market Cap to Net Assets Ratio adctherapeutics.com|ADCT - Cumulative Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio ADC Therapeutics|ADCT - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio ADC Pharma|ADCT - Company Aggregate Debts|Debt to Net Assets Ratio ADC Therapeutics Corp|ADCT - Company Long-Term Debts|Short-Term Debt ADC Therapeutics|Intermediate Coverage Ratio adctherapeutics.com
- net income and valuation multiples indicators:
ADCT - Net Profit|Projected Future Earnings ADC Therapeutics|ADCT - Price to Earnings Ratio|Price to Expected Earnings Ratio ADC Therapeutics S.A.|ADCT - PEG Multiple|Company Value to EBITDA ADC Therapeutics Corp|ADCT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) ADC Therapeutics|ADCT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months adctherapeutics.com|ADCT - Earnings growth in current year|Consensus forecast of earnings per share growth for next year ADC Therapeutics
- issuer revenue and sales details:
ADCT - Revenue and Sales Volume|Company Future Sales Volume adctherapeutics.com|ADCT - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio ADC Therapeutics Corp
General company analysis:adctherapeutics.com, ADCT
Finished products of ADC Therapeutics S.A.

The P/S multiple compares the market value of ADC Therapeutics (ADCT) to its annual revenue, measuring the premium the market is willing to pay per unit of sales. Amid the commercialization of the antibody-drug conjugate platform, the P/S multiple trend reflects investor confidence in overcoming binary risks and the company's ability to scale sales of its blood cancer therapy.

Competing companies

tgtherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple ACLX (Arcellx, Inc.)|P/S Multiple Disc Medicine Inc IRON|Syndax - P/S Multiple|KURA (Kura) - Market Cap to Revenue Ratio|FHTX: P/S Multiple|Market Cap to Revenue vorbio.com|Market Cap to Revenue NKTX|COEP: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue ATNM (Actinium Pharmaceuticals Inc)|Market Cap to Sales Volume ESLA|P/S Multiple CASI (CASI Pharmaceuticals, Inc.)|Market Capitalization-to-Revenue Ratio MRKR|IN8bio - P/S Multiple|Price to Sales Eterna Therapeutics|GT Biopharma Corp (GTBP) - Price-to-Revenue Ratio|Aptose Biosciences - Market Capitalization-to-Revenue Ratio|BPTH (Bio-Path Holdings) - P/S Multiple|P/S Multiple meipharma.com|Price-to-Revenue Ratio Vincerx Pharma, Inc. (VINC)